Mr. President, I ask unanimous consent that at a time determined by the majority leader, after consultation with the Democratic leader, the Senate proceed en bloc to the following bills under the following agreement: H.R. 810, Stem Cell…
Mr. President, I ask unanimous consent that at a time determined by the majority leader, after consultation with the Democratic leader, the Senate proceed en bloc to the following bills under the following agreement:
H.R. 810, Stem Cell Research Enhancement Act, discharged from the HELP Committee; S. 2754, Alternative Pluripotent Stem Cell Therapies Enhancement Act, discharged from the HELP Committee; S. 3504, Fetus Farming Prohibition Act of 2006.
I further ask consent there be a total of 12 hours of debate equally divided between the two leaders or their designees; provided further that no amendments be in order to any of the measures; further, that following the use or yielding back of time the bills be read a third time and the Senate proceed to three consecutive votes in the following order with no intervening action or debate: S. 3504, S. 2754, H.R. 810.
Finally, I ask unanimous consent that any bill that does not receive 60 votes in the affirmative, the vote on passage be vitiated and the bill be returned to its previous status on the calendar or in the HELP Committee; and further, other than as provided in this agreement, it not be in order for the Senate to consider any bill or amendment relating to stem cell research during the remainder of the 109th Congress.
That is correct. Each of these bills will have a 60-vote threshold.
In all likelihood, but at some mutually agreeable time.
Mr. President, I thank the Democratic leader. As he knows, we have been working a long time to bring, in an appropriate fashion, these bills to the floor. The unanimous consent agreement that we just obtained says that we will address three bills--I will have more to say about those shortly--over the course of the 12-hour period and then have the 60-vote threshold on each of those.
It was several weeks ago that I reiterated my commitment to work with my colleagues on both sides of the aisle to bring the debate about Federal funding for stem cell research to the Senate floor. We have been working very hard in meeting after meeting to do just that.
I just propounded a unanimous consent request which was agreed to that had three pieces of legislation--the Alternative Pluripotent Stem Cell Therapies Enhancement Act, the Stem Cell Research Enhancement Act, which is H.R. 810, and the Fetus Farming Prohibition Act of 2006.
I will have a little bit more to say about each of these.
It is my intention, as it is worded in here, that the two of us will agree upon a time. It is my intention after getting over this first hurdle to do this in the not too distant future before we leave.
We will.
Mr. President, I would like to comment a little bit on the approach and the rationale behind these bills which have been a long time in coming. This is a very similar to the approach that we tried about a year ago, but because of timing and a whole host of reasons we couldn't get a unanimous consent agreement. So I am pleased that we are there.
I am pro-life. I personally believe that human life begins at conception in large part because it is the moment that the organism is complete--immature, yes, but complete.
An embryo is nascent human life. It is genetically distinct as that individual; it is biologically human; it is living. This position is consistent with my faith. But to me it isn't just a matter of faith; it is a matter of science.
Our development is this continuous process; it is gradual; it is chronological; and at one point in time all of us in this room were embryos. That embryo is human life at that very earliest stage of development, which is continuous, which again is chronological over time. And accordingly, that embryo has more significance, it has more moral value, and thus it deserves our utmost respect and dignity.
I also believe, as do other scientists--I would say countless other scientists, clinicians, and doctors--that all stem cells, but specifically embryonic stem cells, hold a very specific, unique promise for some therapies and potential cures: diabetes, Parkinson's disease, Alzheimer's, Lou Gehrig's disease, and spinal cord injuries. Stem cells offer hope for treatment that other lines of research simply haven't offered.
Embryonic stem cells are what we call ``pluripotent,'' adult stem cells. You have embryonic stem cells, and these embryonic stem cells are ``pluripotential.'' What that means is that they have two remarkable qualities that really no other cell in the human body has. That is why they are so unique. The embryonic stem cells have the capacity to become any other type of tissue that is unique to them.
Second, they have this remarkable capacity of being able to renew themselves--copy themselves again and again and again and again indefinitely.
It is those two properties, the ability to copy itself over time and to become any sort of tissue, which makes it specifically unique and so remarkable. That is why we have so much potential hope for cure and for therapy.
Right now, there is the challenge; there is the ethical challenge. This is why it is so hard for us and for people all across this country as they listen to the debate; that is, to derive these embryonic stem cells using the technology that we know today. The embryo itself has to be altered in some way or destroyed.
That is the heart of the ethical concern. That is why I have made it clear that while I strongly support Federal funding for embryonic stem cell research, that Federal funding should only be provided within a system, a comprehensive system of ethical oversight, strict safeguards in this ethical system that are overseeing this financial investment. That comprehensive oversight has to have strict safeguards and public accountability. It has to have complete transparency so we ensure that this new research, this evolving research unfolds over time within accepted ethical bounds.
It is interesting. I came to this floor about 5 years ago. It was 5 years ago sometime around either June or July. At that time, I laid out a comprehensive proposal to promote stem cell research within this ethical framework.
That is interesting because I talked about adult stem cells and embryonic stem cells. At that point in time, embryonic stem cells were only 3 years old in terms of discovery. They had been around a long time, but we only discovered them really in about 1998. At that point in time, I proposed 10 specific interdependent principles.
At this juncture, I ask unanimous consent to have printed in the Record those principles.
Mr. President, I also said at the time that policymakers and the public must often reassess the research, this new research, this evolving research and the circumstances under which it is conducted.
As I said then--and I believe now--we must do all we can to pursue promising alternative strategies that hold the same potential, the potential for developing the pluripotent stem cell lines without damaging the embryo, without altering the embryo, without destroying the embryo or nascent human life.
Shortly after that time--that was 5 years ago--the President announced his policy for embryonic stem cell research. That was remarkable at the time. I think it was August 11. It was Federally funded embryonic stem cell research for the first time ever. It did so within that ethical framework. It showed respect for human life.
That is why I believe it is important for us to have this debate on the floor of the Senate.
The policy also restricted the embryonic stem cell funding only to those stem cell lines that had been derived prior to his announcement. That was the cutoff line. At that time it was widely believed that there were 78 such embryonic stem cell lines that would be available for Federal funding; 78 we thought at the time when President put forth his proposal. Unfortunately, over time we have learned that had not been the case. What we thought would have been 78 lines today we realize only became 22 cell lines--22 lines--that are eligible.
Moreover, those lines unexpectedly--we didn't know it at the time. That is why it is so important to constantly come back and modify, if necessary, but reevaluate policies. Those lines unexpectedly after several generations are starting to became less stable and less replicative than we had initially anticipated.
Science is fascinating. Just as an aside, they seem to be acquiring and losing chromosomes. They are losing what we call the normal carrier type. They are potentially losing growth control, all of which means these cell lines out there are less useful in terms of research, in terms of opening up that potential, those possibilities, that hope for cures.
Also, another complication which we didn't realize at the time--some scientists did but we didn't know what the impact would be--all of these cell lines were grown on mouse-feeder cells, which we have learned since will limit their future potential for using those clinically or in clinical therapy in humans. There are concerns, for example, about viral contamination.
These are limitations we didn't realize at the time but we do know today, 5 years later.
While embryonic stem cell research is still in the very early stage, we have to be careful not to over-promise. And when people look at these bills coming through, although we want to open up that possibility for hope, we cannot over-promise.
The limitations we put in place in 2001 will over time show our ability to investigate new treatments for certain diseases--the mouse- feeder cells, the changes that we are seeing in the initial cell lines, the fact that there are fewer cells lines.
Therefore, I think it is the responsible thing for us to do, to come to the floor and consider modifying that policy, updating that policy based on what we have learned, which is why, with reservation, I support the House-passed embryonic stem cell research bill, H.R. 810.
Let me be clear on this particular bill. Because again and again people come forward saying there are so many deficiencies in the bill. And I see deficiencies in the bill. If circumstances were different, I would seek to ensure that a much stronger ethical and scientific oversight mechanism be in place, which is not part of that particular bill. Things like a clear prohibition on financial or other incentives between science and fertility clinics, more explicit requirements around informed consent, all of which is not in that particular bill.
But I have said that we should debate and vote on that House-passed bill. I, thus, have asked that it be included in the package of bills that we put forward for consideration on which we just got by unanimous consent agreement to debate and vote.
Moreover, as we consider embryonic stem cell research, we shouldn't diminish in any way the promise or slow the progress of research on adult stem cells or cells that have pluripotential capability but aren't strictly embryonic stem cells.
To date, adult stem cell research is the only type of stem cell research that is actively used in humans for treatment, for therapy, to cure diseases.
As a transplant surgeon--I transplant hearts and lungs--today we can transplant these adult stem cells. It is life-saving. It has saved the lives of thousands and thousands of people. Part of that is that we have much longer experience with adult stem cells. We have probably three decades of experience
with the adult stem cells. We only have about 8 years of experience with the embryonic stem cells.
With more Federal support and emphasis, newer methods of deriving the pluripotential cells are being developed and have proven themselves in animal models--not yet in humans--fully developed, and we need to continue to support that research. It will have huge scientific and clinical payoffs.
Just as important, they may bridge the moral and ethical differences among people who now hold very different views on stem cell research because these newer alternative methods avoid the destruction of any human embryos. It is these forms of research which may offer not only a way forward to these new treatments and these new cures but also a way out of these ethical dilemmas posed by other forms of research.
That is why in this package I asked the Senate to also continue legislation to enhance this support for alternatives to embryonic stem cell research. I am very pleased that Senators Santorum and Specter have joined together and crafted the Alternative Pluripotent Stem Cell Therapies Enhancement Act, S. 2754, which is similar to legislation I worked on with a number of our colleagues--most specifically Senator Isakson from Georgia--last year. I do encourage every Senator to support these new alternative ways of reaching pluripotency in cells. It is very exciting research. There is no reason this legislation should not truly unite us as a body and be something everyone can support.
The third bill that has been included in this unanimous consent request is the Fetus Farming Prohibition Act of 2006, S. 3504. One may ask, what is fetus farming? It is the implantation and gestation of an embryo in a human or animal for the purpose of aborting for research. As far as I am aware, fetus farming is not a method that is currently employed but a method that has been proposed. It is not out of the realm of possibility. Therefore, Senators Brownback and Santorum have proposed legislation which would draw a clear line which should not be crossed.
Those are the three bills which we will be debating. Several of my colleagues on the other side of the aisle have come to the Senate over the last several weeks and months to suggest we take up H.R. 810 or that we immediately take it up. However, I am absolutely convinced that all three bills I have mentioned address the profound ethical questions surrounding the promise of stem cells, the hope that these stem cells will lead to cure and therapy. That is why I believe it is only fair on an issue of this magnitude that Senators be given the courtesy and respect of addressing all three of these very different ideas, these areas which are surrounded in some ethical concern but also are important to medicine, science, and health.
The other proposals for handling this include taking a bill out and seeing what happens. Because these bills are so complex and Members have so many potential amendments, we have taken this course of having 3 bills with the 60-vote thresholds.
I thank my colleagues. We covered the spectrum. It has actually taken several months to pull together this unanimous consent request and agreement. I am very pleased we now have a process in place, the timing of which we can determine or I will determine in consultation with my colleagues on both sides of the aisle